Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.

Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A.

Cell Cycle. 2009 Jan 1;8(1):172-5. Epub 2009 Jan 30. No abstract available.

PMID:
19106613
2.

MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.

Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, Chen T, Luo Y.

Cancer Genet. 2012 Mar;205(3):113-23. doi: 10.1016/j.cancergen.2012.01.002.

PMID:
22469510
3.

Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.

Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ, Zhao Q.

Carcinogenesis. 2011 Jan;32(1):2-9. doi: 10.1093/carcin/bgq209. Epub 2010 Oct 15.

PMID:
20952513
4.

Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.

Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, Yue S, O'Sullivan B, Liu FF.

Cell Death Dis. 2010 Oct 21;1:e85. doi: 10.1038/cddis.2010.64.

5.

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.

Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodríguez-González FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2012 Jun;133(3):937-47. doi: 10.1007/s10549-011-1877-4. Epub 2011 Nov 18.

6.

The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer.

Friedman JM, Jones PA, Liang G.

Cell Cycle. 2009 Aug;8(15):2313-4. Epub 2009 Aug 15. No abstract available.

7.

The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.

Sakurai T, Bilim VN, Ugolkov AV, Yuuki K, Tsukigi M, Motoyama T, Tomita Y.

Biochem Biophys Res Commun. 2012 Jun 15;422(4):607-14. doi: 10.1016/j.bbrc.2012.05.035. Epub 2012 May 15.

8.

MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.

Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M, Sui G.

Mol Cancer. 2010 May 17;9:108. doi: 10.1186/1476-4598-9-108.

9.

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.

Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM.

Science. 2008 Dec 12;322(5908):1695-9. doi: 10.1126/science.1165395. Epub 2008 Nov 13.

10.

Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.

Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM.

Oncotarget. 2011 Sep;2(9):669-83.

11.

Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2.

Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM, Fusco A.

J Clin Endocrinol Metab. 2012 May;97(5):E710-8. doi: 10.1210/jc.2011-3068. Epub 2012 Mar 7.

PMID:
22399519
12.

MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.

Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, Li XP.

Cancer Res. 2011 Jan 1;71(1):225-33. doi: 10.1158/0008-5472.CAN-10-1850.

13.

MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.

Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Möller P, Stilgenbauer S, Pollack JR, Wirth T.

Blood. 2008 Nov 15;112(10):4202-12. doi: 10.1182/blood-2008-03-147645. Epub 2008 Aug 19.

14.

The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.

Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W, Zhou X, Jones PA.

Cancer Res. 2009 Mar 15;69(6):2623-9. doi: 10.1158/0008-5472.CAN-08-3114. Epub 2009 Mar 3.

15.

[Recent advances on EZH2 in malignant tumors].

Li J, Fan QH.

Zhonghua Bing Li Xue Za Zhi. 2009 Dec;38(12):856-8. Review. Chinese. No abstract available.

PMID:
20193471
16.

Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.

Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Sarkar FH.

Cancer Res. 2012 Jan 1;72(1):335-45. doi: 10.1158/0008-5472.CAN-11-2182. Epub 2011 Nov 22.

17.

Repression of E-cadherin by the polycomb group protein EZH2 in cancer.

Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM.

Oncogene. 2008 Dec 11;27(58):7274-84. doi: 10.1038/onc.2008.333. Epub 2008 Sep 22.

18.

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.

Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H.

Cancer. 2010 Jun 15;116(12):3015-24. doi: 10.1002/cncr.25128.

19.

Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.

Fujii S, Ochiai A.

Cancer Sci. 2008 Apr;99(4):738-46. doi: 10.1111/j.1349-7006.2008.00743.x.

20.

Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.

Karanikolas BD, Figueiredo ML, Wu L.

Mol Cancer Res. 2009 Sep;7(9):1456-65. doi: 10.1158/1541-7786.MCR-09-0121. Epub 2009 Sep 1.

Supplemental Content

Support Center